Results 121 to 130 of about 170,525 (342)

AI‐Assisted Drug Re‐Purposing for Human Liver Fibrosis

open access: yesAdvanced Science, EarlyView.
A multi‐agent AI (AI co‐scientist) is used to repurpose drugs for liver fibrosis treatment and to guide their experimental characterization. The anti‐fibrotic efficacy and toxicity of these drugs is assessed in multi‐lineage human hepatic organoids grown in microwells (microHOs).
Yuan Guan   +20 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

Pimpinella anisum L. fruit: Chemical composition and effect on rat model of nonalcoholic fatty liver disease

open access: yesJournal of Research in Medical Sciences, 2017
Background: Nonalcoholic fatty liver disease (NAFLD) includes a group of chronic liver disorders caused by irregular accumulation of fat in liver tissue.
Ali Asadollahpoor   +2 more
doaj   +1 more source

New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. [PDF]

open access: yes, 2018
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. HCC initiates as a consequence of chronic liver damage and inflammation caused by hepatitis B and C virus infections, excessive alcohol consumption, or non ...
Karin, Michael
core   +1 more source

Nutritional c‐Fos Induction Rewires Hepatic Metabolism and Can Promote Obesity‐Associated Hepatocellular Carcinoma

open access: yesAdvanced Science, EarlyView.
It is shown that hepatic c‐Fos responds to feeding, altering de novo lipogenesis, glycolysis, and a wide range of steatosis‐associated metabolic signaling pathways. Obesogenic diets cause hepatic c‐Fos overexpression, insulin resistance, and the induction of metabolic reprogramming‐related genes.
Ao Li   +8 more
wiley   +1 more source

Functional condition of the stomach,pancreas, liver, ulcer and gall-bladder in celiac disease

open access: yesТерапевтический архив, 2011
Aim. To study condition of the stomach, gall-bladder, pancreas, liver in celiac disease (CD) and contribution of their dysfunction to clinical presentation of CD symptoms. Material and methods.
Larisa Matisovna Krums   +5 more
doaj  

Are transmembrane 6 superfamily member 2 gene polymorphisms associated with steatohepatitis after pancreaticoduodenectomy?

open access: yesJGH Open
Aim After pancreaticoduodenectomy, 20–40% of patients develop steatotic liver disease (SLD), and steatohepatitis can be a problem. Although patatin‐like phospholipase domain‐containing 3 protein (PNPLA3) and transmembrane 6 superfamily member 2 (TM6SF2 ...
Tomotaka Mori   +18 more
doaj   +1 more source

Research landscape and frontiers of non-alcoholic steatohepatitis-associated hepatocellular carcinoma: a bibliometric and visual analysis [PDF]

open access: gold, 2023
Bowen Gao   +7 more
openalex   +1 more source

Effect of Wakame and Carob Pod Snacks on Non-Alcoholic Fatty Liver Disease [PDF]

open access: yes, 2019
Snacks combining different functional ingredients could represent a useful therapeutic strategy against NAFLD. The present study aimed to analyze the effect of two snack formulations based on carob and wakame flour in the treatment for NAFLD in rats. For
Aguirre López, Leixuri   +6 more
core   +2 more sources

Ubc9‐Mediated SUMOylation of RPL3, an Unappreciated Mechanism against Hepatocyte Senescence by Repressing the DHX9‐p16 Axis

open access: yesAdvanced Science, EarlyView.
Liver aging is characterized by a decline in the expression of the SUMO‐conjugating enzyme Ubc9, resulting in reduced SUMOylation levels in hepatocytes, particularly in the case of ribosomal protein RPL3. Disruption of RPL3 SUMOylation increases its nuclear translocation. Interestingly, ribosome‐free RPL3 facilitates the recruitment of helicase DHX9 to
Hao Xie   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy